A viral study claim surfaced
A social post circulated a study claiming ivermectin produced positive outcomes in about 84% of nearly 200 cancer patients — broken down as roughly 48% remission/no evidence and 36% no disease progression (x.com). The post sparked debate across fitness and health feeds as audiences questioned methods and veracity of the reported results (x.com).
The viral “84% benefit” figure came from a company news release about an unpublished observational report, not from a randomized cancer trial. (twc.health) The April 7, 2026 release from The Wellness Company said its manuscript was “currently under peer review” and described 197 cancer patients who were prescribed off-label ivermectin plus mebendazole. It said patients took compounded capsules with 25 milligrams of ivermectin and 250 milligrams of mebendazole. (twc.health) The company said that after six months, 48% of participants reported regression or no evidence of cancer, 36% reported stable disease, and 15.6% reported progression. The same release described the finding as a “prospective real-world cohort” and said the outcomes were self-reported. (twc.health) Ivermectin is a drug approved for parasitic infections, and cancer studies have mostly been lab and animal work that test whether it can slow tumor cells, the way a screening experiment tests a lead before human trials. A 2025 review in *Current Oncology Reports* said human evidence remains limited and that no large randomized controlled trials have confirmed a cancer benefit. (springer.com) A separate 2025 review in *Pharmaceuticals* said ivermectin affects cancer-related pathways in preclinical research but that “clinical validation remains limited” and called for robust trials on safety and efficacy in oncology. That is the gap between a lab signal and a treatment doctors can rely on in routine care. (pmc.ncbi.nlm.nih.gov) ClinicalTrials.gov lists a Phase 2 study at Cedars-Sinai testing ivermectin with balstilimab or pembrolizumab in metastatic triple-negative breast cancer, with no results posted. The trial record says it is evaluating side effects, dosing, and outcomes such as response rate, progression-free survival, overall survival, and clinical benefit rate. (clinicaltrials.gov) The National Cancer Institute also lists a pembrolizumab-ivermectin trial for metastatic triple-negative breast cancer, but its page shows the study as withdrawn. That means there is at least some formal cancer-trial interest in ivermectin, but not published proof that it works across cancers. (cancer.gov) Mainstream cancer guidelines available through the National Comprehensive Cancer Network’s 2026 navigator cover standard treatments across more than a dozen tumor types, and the public guideline index does not identify ivermectin as a listed standard therapy. The viral post’s numbers therefore sit outside current guideline-based cancer care. (nccn.org) The 84% figure can be checked only when the underlying paper, methods, patient selection, imaging review, and comparison data are public. Until then, the claim is a company-reported, self-reported observational result about ivermectin plus mebendazole, not settled evidence that ivermectin treats cancer. (twc.health)
